| |
|
|
|
CytomX Therapeutics Inc.  
|
|
7.4 0.22 (0.03%) |
09-18 16:00 |
|
Open: |
7.27 |
Pre close: |
7.18 |
Target:
|
8.80
|
|
High: |
7.44 |
Low: |
7.04 |
Resistance:
|
7.53
8.80
|
|
Volume: |
898,893 |
Market Cap: |
342M |
Support:
|
6.74
6.25
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
7.26
 |
MACD |
MACD(12,26):
|
-0.04 |
|
MA(20): |
7.01 |
Signal(12,26,9): |
-0.13 |
|
MA(100): |
8.40  |
Stochastic Oscillator |
%K(14,3):
|
81.97 |
|
MA(250): |
7.64 |
%D(3): |
81.49 |
|
Average Volume(K) |
3-Month: |
42474
|
52-Week |
High:
|
15.44 |
|
10-Days: |
56308 |
Low: |
3.60 |
|
RSI |
RSI(14):
|
55.60 |
Change(%): |
-15.6 |
|
Financials, Statistics and Valuation |
|
EPS |
-1.370 |
Return on Equity (ttm) |
-78.1 |
Shares Out. (M) |
46.19 |
|
EPS Est. Current Year |
-1.490 |
Return on Assets (ttm) |
-12.7 |
Shares Float (M) |
36.57 |
|
EPS Est. Next Year |
-1.410 |
PEG Ratio |
0.00 |
% Held by Insiders |
2.30 |
|
EPS Est. Next Quarter |
-0.410 |
Qtrly Rev. Growth |
84.3 |
% Held by Institutions |
84.32 |
|
Forward EPS |
-2.260 |
Gross Profit (p.s.) |
1.245 |
Shares Short (K) |
3510 |
|
Book Value (p.s.) |
1.270 |
EBITDA (p.s.) |
-1.721 |
P/E |
-5.40 |
|
Sales Per Share |
1.844 |
Qtrly Earnings Growth |
0.00 |
P/BV |
5.83 |
|
Profit Margin |
-73.51 |
Operating Cash Flow
(M) |
-5.43 |
P/S |
4.01 |
|
Operating Margin |
-96.29 |
Levered Free Cash Flow
(M) |
-18.05 |
P/CF |
-62.95 |
|
|
|
|
|
|
